3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
17
Gastrointestinal Stromal Tumors
10
Neoplasms
5
Neoplasm Metastasis
4
Multiple Myeloma
4
Kidney Neoplasms
4
Urologic Neoplasms
2
Thyroid Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Meningioma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Kidney Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rectal Neoplasms
1
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
Nivolumab
6
atezolizumab
5
Cisplatin
5
Ipilimumab
4
Carboplatin
4
Etoposide
3
pembrolizumab
2
gallium Ga 68 dotatate
2
dostarlimab
2
Temozolomide
2
Positron Emission Tomography Computed Tomography
2
Paclitaxel
2
Magnetic Resonance Imaging
2
Irinotecan
2
Immunoglobulin G
2
IFL protocol
2
Disulfides
2
zimberelimab
1
tivozanib
1
repotrectinib
1
niraparib
1
lutetium Lu 177 dotatate
1
lenvatinib
1
iadademstat
1
durvalumab
1
cabozantinib
1
budigalimab
1
belinostat
1
Topotecan
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Neuroendocrine
×
Sunitinib
×
1 year
×
Clear all
No trials found.